Are Peptides Legal in Nevada? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Nevada as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Nevada attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Nevada statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. Nevada does go further on at least one compound: Human growth hormone (somatropin), Schedule III, Chorionic gonadotropin (hCG), Schedule III (details below). Nevada also lists human growth hormone in its own controlled-substance law, on top of the federal rule. The Nevada Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Nevada at a glance

State controlled-substances law: Nev. Rev. Stat. Chapter 453, Uniform Controlled Substances Act (NRS 453.011 et seq.); schedules adopted by the State Board of Pharmacy by regulation at NAC 453.510 to 453.550 (nevada.public.law)
Human growth hormone under state law: Listed as a controlled substance in state law (NAC 453.530(13)) (law.cornell.edu)
Research peptides scheduled by the state: Human growth hormone (somatropin), Schedule III (NAC 453.530(13)) (law.cornell.edu), Chorionic gonadotropin (hCG), Schedule III (NAC 453.530(7)(h) and (8)) (law.cornell.edu)
Board of Pharmacy on compounded GLP-1s: A State Board of Pharmacy licensee notice (2 June 2025) relayed the FDA's declaratory orders: 503A and 503B pharmacies may no longer compound, distribute or dispense compounded tirzepatide injections, and 503A pharmacies may no longer compound semaglutide injections (503B facilities from 22 May 2025). It reminds 503A pharmacies they may not sell compounded drugs to practitioners, points to the NAC 639.757 compounding limits, and warns that continued compounding or wholesaling of federally restricted drugs violates Nevada pharmacy law with citations and fines under NRS 639.2895 (2025-06-02) (bop.nv.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. NRS 629.515 requires the distant-site provider to hold a Nevada licence and allows a relationship to be established by telehealth when clinically appropriate; there is no in-person examination requirement and no questionnaire ban for non-controlled drugs, but the provider must meet the same standard of care as in person. (codes.findlaw.com)
State-level enforcement, 2023 to 2026: 4 actions found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Nevada, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Nevada:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Nevada. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Nevada law adds

Nevada's controlled-substances law (Nev. Rev. Stat. Chapter 453, Uniform Controlled Substances Act (NRS 453.011 et seq.); schedules adopted by the State Board of Pharmacy by regulation at NAC 453.510 to 453.550) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (nevada.public.law)

Compounds Nevada has scheduled or restricted

Human growth hormone (somatropin), Schedule III (NAC 453.530(13)) (law.cornell.edu)
Chorionic gonadotropin (hCG), Schedule III (NAC 453.530(7)(h) and (8)) (law.cornell.edu)

Human growth hormone

Nevada goes beyond federal law: the Board of Pharmacy has placed human growth hormone on state Schedule III by regulation (NAC 453.530(13)). Possession without a prescription therefore falls under NRS 453.336. (NAC 453.530(13)) (law.cornell.edu)

Compounded semaglutide and tirzepatide

2025-06-02. A State Board of Pharmacy licensee notice (2 June 2025) relayed the FDA's declaratory orders: 503A and 503B pharmacies may no longer compound, distribute or dispense compounded tirzepatide injections, and 503A pharmacies may no longer compound semaglutide injections (503B facilities from 22 May 2025). It reminds 503A pharmacies they may not sell compounded drugs to practitioners, points to the NAC 639.757 compounding limits, and warns that continued compounding or wholesaling of federally restricted drugs violates Nevada pharmacy law with citations and fines under NRS 639.2895. (bop.nv.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Nevada medical board guidance specific to peptide therapy was located. A Nevada prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Nevada

Possessing HGH or hCG without a prescription is a controlled-substance offence in Nevada (NRS 453.336) because both are on state Schedule III; unscheduled peptides such as BPC-157 or TB-500 are not covered by that section, but NRS 454.316 separately makes possession of any prescription-only dangerous drug without a prescription a gross misdemeanor, so a compounded or prescription-only peptide held without a prescription can still be charged. (nevada.public.law)

Ordering from a vendor in another state. Almost every research-peptide order into Nevada is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. NRS 629.515 requires the distant-site provider to hold a Nevada licence and allows a relationship to be established by telehealth when clinically appropriate; there is no in-person examination requirement and no questionnaire ban for non-controlled drugs, but the provider must meet the same standard of care as in person. (codes.findlaw.com) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Nevada law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Nevada

2023-06-09. The State Board of Pharmacy confirmed several open investigations into sales of substances marketed as semaglutide for weight loss, working with the FDA on salt-form and legitimacy concerns. (8newsnow.com)
2024-09-12. The Board of Pharmacy issued a cease and desist, a citation and a $655,000 fine to Texas-based Nova Specialty Pharmacy for dispensing more than 100 prescriptions, including compounded semaglutide, to Nevadans without a Nevada licence. (reviewjournal.com)
2025-02-19. Nevada's attorney general signed the 38-state letter urging the FDA to act against counterfeit and illegally sold GLP-1 drugs, including research-only labelled product. (naag.org)
2025-06-02. The Board of Pharmacy ordered all Nevada-licensed pharmacies to cease compounding, distributing and dispensing compounded tirzepatide and semaglutide injections, with fines for non-compliance. (bop.nv.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. Nevada is one of the few states that schedules both HGH and hCG at state level. No Board of Medical Examiners statement on research peptides, BPC-157 or medspas was found; enforcement to date has come from the Board of Pharmacy.

Frequently asked questions

Is BPC-157 legal in Nevada?

Nevada has not scheduled BPC-157, so possessing it is not a Nevada offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Nevada?

Yes. NRS 629.515 requires the distant-site provider to hold a Nevada licence and allows a relationship to be established by telehealth when clinically appropriate; there is no in-person examination requirement and no questionnaire ban for non-controlled drugs, but the provider must meet the same standard of care as in person. The Nevada Board of Pharmacy position on compounded versions: A State Board of Pharmacy licensee notice (2 June 2025) relayed the FDA's declaratory orders: 503A and 503B pharmacies may no longer compound, distribute or dispense compounded tirzepatide injections, and 503A pharmacies may no longer compound semaglutide injections (503B facilities from 22 May 2025). It reminds 503A pharmacies they may not sell compounded drugs to practitioners, points to the NAC 639.757 compounding limits, and warns that continued compounding or wholesaling of federally restricted drugs violates Nevada pharmacy law with citations and fines under NRS 639.2895.

Is HGH legal in Nevada?

Only with a valid prescription. Nevada lists human growth hormone as a controlled substance and federal law, 21 U.S.C. section 333(e), separately makes distribution or possession for a non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Nevada fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.